ImmunityBio (IBRX) Minority Interest (2020 - 2026)

ImmunityBio (IBRX) has 7 years of Minority Interest data on file, last reported at $880000.0 in Q1 2026.

• On a quarterly basis, Minority Interest fell 7.27% year-over-year to $880000.0 in Q1 2026; TTM through Mar 2026 was $880000.0, a 7.27% decrease from a year earlier, with the FY2025 full-year figure at $895000.0, down 7.64% from the prior year.
• Minority Interest for Q1 2026 stood at $880000.0, down from $895000.0 in the prior quarter.
• Over the last five years, Minority Interest for IBRX reached as high as $1.1 million in Q3 2023 and fell as low as -$3.1 million in Q2 2023.
• Historically, Minority Interest has averaged -$239294.1 across 5 years, with a median of $909000.0 in 2025.
• Across the five-year window, Minority Interest tumbled 523.95% in 2022 and jumped 145.0% in 2023, its largest moves.
• Year by year, Minority Interest stood at -$2.5 million in 2022, then surged by 142.12% to $1.0 million in 2023, then slipped by 7.71% to $969000.0 in 2024, then fell by 7.64% to $895000.0 in 2025, then retreated by 1.68% to $880000.0 in 2026.
• Per Business Quant data, the three most recent Minority Interest figures were $880000.0 in Q1 2026, $895000.0 in Q4 2025, and $909000.0 in Q3 2025.